Betadine
ApprovedSmall molecule
Betadine is one of 23 small molecule programs targeting Granuloma. It is currently in Approved.
1
Indications
8
Total Trials
0
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
35 competitors in Granuloma
#DrugCompanyPhaseTrials
1Medrol
PfizerApproved
Rayos
RRoxane Laboratories
Approved
Compound Betamethasone
SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Approved
Enbrel
IImmunex
Phase 3
Nexium
DDexcel Pharma Technologies Ltd.
Phase 3
Zinbryta
RochePhase 2
Intron a
SanofiPhase 2
Olumiant
Eli LillyPhase 2
Orencia
Bristol-Myers SquibbPhase 2
Prilosec
DDexcel Pharma Technologies Ltd.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Surgery1 trial
Cardiac Surgery1 trial
Efficacy of Diluted Betadine vs Antibiotic Installation Before Surgical Wound Closure in Prevention of Post Cardiac Surgery Wound Infection
Unknown status·—·Phase 4·NCT05276687·80 enrolled
MPA1 trial
3 more indications
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Betadine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- EEgymedicalpedia